USA ISM Non-Manufacturing PMI for Aug 56.900 vs 55.100 Est; Prior 56.700
USA ISM Non-Manufacturing PMI for Aug 56.900 vs 55.100 consensus estimate. The prior reading was 56.700.
Creatd Executive Chairman Jeremy Frommer To Assume CEO Role
Executive Chairman of the Board, Jeremy Frommer will assume the CEO seat.
Creatd's board significantly amplifies its capabilities with the addition of Justin Maury, Creatd's COO and Co-founder.
NEW YORK,
Executive Chairman of the Board, Jeremy Frommer will assume the CEO seat.
Heritage Global Partners Awarded New Global Vendor Contract With Pfizer
Multi-Year Contract to Begin on January 1, 2023
SAN DIEGO--(BUSINESS WIRE)-- Heritage Global Partners (“HGP”), a worldwide leader in asset advisory and auction services, and a subsidiary of Heritage Global
ADT Announces State Farm Will Invest $1.2B In Co. At $9/Share, Acquiring ~15% Of Co. And Additionally Investing Up To $300M In Opportunity Fund; Google Commits Incremental $150M Into Success Fund
New integrated offering aims to deliver substantial customer value with smart home technology to detect and mitigate losses related to water, fire, intrusion and other homeownership-related risks
State Farm to invest
FDA And Health Canada Clear IND For FSD Pharma To Proceed With Phase 2 Trial Of FSD201 For Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to
Sonim Technologies Announces $9M Tablet Purchase Order
Austin, Texas--(Newsfile Corp. - September 6, 2022) - Sonim Technologies (NASDAQ:SONM) today announced a customer purchase order for $9 million to purchase tablet products designed by Sonim and
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting With FDA; Announces ‘Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr’
Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr
FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients with
Soligenix Announces FDA Awards $2.6M Orphan Products Development Grant For Expanded Study Of HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Grant supports study of expanded HyBryte™ treatment, including in the Home Use Setting
PRINCETON, N.J., Sept. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage
Dyne Therapeutics Announces First Patient Dosed In Phase 1/2 DELIVER Clinical Trial Of DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy
Data from Global, Multiple Ascending Dose DELIVER Trial Anticipated in the Second Half of 2023 -
- Dyne to Host “Spotlight on the Clinic” Virtual Event on September 12 -
WALTHAM, Mass., Sept. 06, 2022
Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 At International Congress Of The Transplantation Society
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced three oral presentations by academic collaborators at the 29th International Congress